دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Improving neurological services in and out of Africa
doi : 10.1016/S1474-4422(23)00472-6
Volume 23, Issue 1, January 2024, Page 1
The long road to neuroprotection for Parkinson's disease
Claudia Trenkwalder, Brit Mollenhauer
doi : 10.1016/S1474-4422(23)00462-3
Volume 23, Issue 1, January 2024, Pages 2-3
Anticoagulants to prevent recurrent non-cardioembolic stroke
Pooja Khatri
doi : 10.1016/S1474-4422(23)00464-7
Volume 23, Issue 1, January 2024, Pages 3-5
Cerliponase alfa and neuronal ceroid lipofuscinosis type 2: long-term outcomes and lessons for future research
Rose-Mary Boustany
doi : 10.1016/S1474-4422(23)00467-2
Volume 23, Issue 1, January 2024, Pages 5-7
Physiological trajectories after traumatic brain injury: markers or makers of disease?
Ruchira M Jha, *Patrick M Kochanek
doi : 10.1016/S1474-4422(23)00428-3
Volume 23, Issue 1, January 2024, Pages 7-9
Reassessing the implications of atrial fibrillation detected after stroke
Hooman Kamel
doi : 10.1016/S1474-4422(23)00406-4
Volume 23, Issue 1, January 2024, Pages 9-11
Stroke advances in 2023: a new horizon for the management of intracerebral haemorrhage
Craig S Anderson
doi : 10.1016/S1474-4422(23)00451-9
Volume 23, Issue 1, January 2024, Pages 12-13
Dementia research in 2023: the year of anti-amyloid immunotherapy
*Julien Delrieu, Sandrine Andrieu, Bruno Vellas
doi : 10.1016/S1474-4422(23)00449-0
Volume 23, Issue 1, January 2024, Pages 13-15
Highlights in traumatic brain injury research in 2023
*Andrew I R Maas, David K Menon
doi : 10.1016/S1474-4422(23)00458-1
Volume 23, Issue 1, January 2024, Pages 15-17
Headache research in 2023: advancing therapy and technology
*Simona Sacco, Raffaele Ornello
doi : 10.1016/S1474-4422(23)00450-7
Volume 23, Issue 1, January 2024, Pages 17-19
Major advances in epilepsy research in 2023
*Patrick W Hullett, Daniel H Lowenstein
doi : 10.1016/S1474-4422(23)00457-X
Volume 23, Issue 1, January 2024, Pages 19-20
Important advances in movement disorders research in 2023
Jung Hwan Shin, Han-Joon Kim, *Beomseok Jeon
doi : 10.1016/S1474-4422(23)00461-1
Volume 23, Issue 1, January 2024, Pages 20-22
Multiple sclerosis in 2023: beyond the boundaries
Carmen Tur, *Mar Tintoré
doi : 10.1016/S1474-4422(23)00459-3
Volume 23, Issue 1, January 2024, Pages 22-24
Therapeutic advances in neuromuscular diseases in 2023
John Vissing
doi : 10.1016/S1474-4422(23)00465-9
Volume 23, Issue 1, January 2024, Pages 24-25
Sleep research in 2023: beyond the bare necessities
Federica Provini
doi : 10.1016/S1474-4422(23)00466-0
Volume 23, Issue 1, January 2024, Pages 25-27
Pain research in 2023: towards understanding chronic pain
*Claudia Sommer, Heike Rittner
doi : 10.1016/S1474-4422(23)00446-5
Volume 23, Issue 1, January 2024, Pages 27-28
Neuropsychiatric research in 2023: mechanisms of stress and therapies
Juan Pablo Lopez, *Alon Chen
doi : 10.1016/S1474-4422(23)00469-6
Volume 23, Issue 1, January 2024, Pages 28-30
Neurological infections in 2023: surveillance and prevention
*Diederik van de Beek, Matthijs C Brouwer
doi : 10.1016/S1474-4422(23)00445-3
Volume 23, Issue 1, January 2024, Pages 30-32
Correction to Lancet Neurol 2024; 23: 110–22
doi : 10.1016/S1474-4422(23)00444-1
Volume 23, Issue 1, January 2024, Page e1
Claudia Sommer: solving puzzles in neuropathic pain
Jules Morgan
doi : 10.1016/S1474-4422(23)00477-5
Volume 23, Issue 1, January 2024, Page 33
Walker's miracle of science
Mark Weatherall
doi : 10.1016/S1474-4422(23)00324-1
Volume 23, Issue 1, January 2024, Page 34
A memoir of multiple sclerosis
Declan T Chard
doi : 10.1016/S1474-4422(23)00474-X
Volume 23, Issue 1, January 2024, Page 35
More than a century of ideas about epilepsy
Guenter Kraemer
doi : 10.1016/S1474-4422(23)00476-3
Volume 23, Issue 1, January 2024, Page 36
Innovation in the prevention of neurological diseases
Georgia Bibas
doi : 10.1016/S1474-4422(23)00475-1
Volume 23, Issue 1, January 2024, Page 36
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Andrew McGarry, Shane Rosanbalm, Mika Leinonen, C Warren Olanow, Dennis To, Adam Bell, Daniel Lee, Jamie Chang, Jordan Dubow, Rohit Dhall, Daniel Burdick, Sotirios Parashos, Jeanne Feuerstein, Joseph Quinn, Rajesh Pahwa, Mitra Afshari, Aldolfo Ramirez-Zamora, Kelvin Chou, Arjun Tarakad, Corneliu Luca, Kevin Klos, Yvette Bordelon, Marie-Helene St Hiliare, David Shprecher, Seulki Lee, Ted M Dawson, Viktor Roschke, Karl Kieburtz
doi : 10.1016/S1474-4422(23)00378-2
Volume 23, Issue 1, January 2024, Pages 37-45
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial
Mukul Sharma, Carlos A Molina, Kazunori Toyoda, Daniel Bereczki, Shrikant I Bangdiwala, Scott E Kasner, Helmi L Lutsep, Georgios Tsivgoulis, George Ntaios, Anna Czlonkowska, Ashfaq Shuaib, Pierre Amarenco, Matthias Endres, Byung-Woo Yoon, David Tanne, Danilo Toni, Laetitia Yperzeele, Paul von Weitzel-Mudersbach, Gisele Sampaio Silva, Alvaro Avezum, Jesse Dawson, Daniel Strbian, Turgut Tatlisumak, Jens Eckstein, Sebasti?n F Ameriso, Joerg R Weber, Else Charlotte Sandset, Nana Goar Pogosova, Pablo M Lavados, Antonio Arauz, David Gailani, Hans-Christoph Diener, Richard A Bernstein, Charlotte Cordonnier, Anja Kahl, Grigor Abelian, Mark Donovan, Chahin Pachai, Danshi Li, Graeme J Hankey
doi : 10.1016/S1474-4422(23)00403-9
Volume 23, Issue 1, January 2024, Pages 46-59
Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study
Angela Schulz, Nicola Specchio, Emily de los Reyes, Paul Gissen, Miriam Nickel, Marina Trivisano, Shawn C Aylward, Anupam Chakrapani, Christoph Schwering, Eva Wibbeler, Lena Marie Westermann, Douglas J Ballon, Jonathan P Dyke, Anu Cherukuri, Shailesh Bondade, Peter Slasor, Jessica Cohen Pfeffer
doi : 10.1016/S1474-4422(23)00384-8
Volume 23, Issue 1, January 2024, Pages 60-70
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study
Cecilia A I ?kerlund, Anders Holst, Shubhayu Bhattacharyay, Nino Stocchetti, Ewout Steyerberg, Peter Smielewski, David K Menon, Ari Ercole, David W Nelson, on behalf of the CENTER-TBI participants and investigators
doi : 10.1016/S1474-4422(23)00358-7
Volume 23, Issue 1, January 2024, Pages 71-80
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes
Antonio Farina, Macarena Villagr?n-Garc?a, Alberto Vogrig, Anastasia Zekeridou, Sergio Mu?iz-Castrillo, Roser Velasco, Amanda C Guidon, Bastien Joubert, Jérôme Honnorat
doi : 10.1016/S1474-4422(23)00369-1
Volume 23, Issue 1, January 2024, Pages 81-94
Blood–brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies
Bettina Zierfuss, Catherine Larochelle, Alexandre Prat
doi : 10.1016/S1474-4422(23)00377-0
Volume 23, Issue 1, January 2024, Pages 95-109
Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack
Luciano A Sposato, Thalia S Field, Renate B Schnabel, Rolf Wachter, Jason G Andrade, Michael D Hill
doi : 10.1016/S1474-4422(23)00326-5
Volume 23, Issue 1, January 2024, Pages 110-122
